The US Food and Drug Administration (HKG:9926) approved Akeso's penpulimab-kcqx combination with cisplatin or carboplatin and gemcitabine for the treatment of nasopharyngeal carcinoma.
The drug, a differentiated PD-1 monoclonal antibody, is indicated for the treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma in adults, according to a Friday filing with the Hong Kong bourse.
Chinese authorities have already approved the drug for first-line treatment of advanced nasopharyngeal carcinoma and second or later-line treatment of advanced nasopharyngeal carcinoma, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.